GI bleeding

Upper GI bleed (UGIB)

  • Upper GI bleeding can be divided into variceal and non-variceal causes, because of important differences in Mx strategies

History Likely cause
NSAID use, previous ulcer,systemic illness Peptic ulcer disease/gastroduodenitis
Alcohol excess, chronic liver disease, spider naevi, jaundice, hepatosplenomegaly, encephalopathy, ascites *Varices / portal hypertensive gastropathy
Excessive retching and vomiting prior to haematemesis Mallory-Weiss tear
Weight loss, dysphagia Stricture/malignancy
Chronic reflux, bisphosphonate use Oesophagitis
Previous abdominal aortic aneurysm repair Aorto-enteric fistula
Chronic kidney disease Vascular ectasia
Recent endoscopic retrograde cholangiopancreatography Post-sphincterotomy bleed
Peritonitis Perforated ulcer
Cachexia/lymphadenopathy Malignancy
causes of UGIB in UK


Assess Risk:

Blatchford Score
Rockall score
  • Blatchford score at first assessment, and
  • full Rockall score after endoscopy
  • A patient with a Blatchford score of 0,1 may be discharged with O/P endoscopy
  • AIMS65 score (not currently used in UK) probably superior to both in predicting I/P mortality, LOS and likely ICU admission
    • Score of ≥2 predicts high mortality - 1 point for each : Albumin <30, INR>1.5, alteration in mental state, sBP<90, age ≥65

Management

  • Transfusion if massive bleeding with blood, platelets and clotting factors
  • platelets not required if no active bleeding and haemodynamically stable.
  • prothrombin complex concentrate if taking warfarin
  • Do not use recombinant factor Vlla except when all other methods have failed
  • terlipressin for patients with suspected variceal bleeding at presentation
    • synthetic vasopressin analogue with relative specificity for splanchnic circulation
    • causes vasoconstriction leading to a reduction in portal pressure
    • Dose: 1-2mg per 6/24
  • prophylactic antibiotic therapy at presentation to patients with suspected or confirmed variceal bleeding.
  • no evidence to support TXA in GI bleeding.

Lower GI bleeding

  • Haemorrhoids
  • Anal fissure
  • Anorectal ulceration
  • Inflammatory bowel disease (IBD)
  • Coeliac disease
  • Diverticular disease
  • Ischaemic colitis
  • Infective colitis
  • Cancer (Lower GI)
  • Angioectasia
  • Drugs (NSAIDs, warfarin or DOACs)
  • Upper GI bleeding presenting as LGIB

1st stratify as unstable vs stable: Unstable = shock index(SI) >1:

  • SI is defined as heart rate (HR) divided by systolic blood pressure (SBP)
  • SI greater than or equal to 1.0 was associated with 40% mortality
  • SI has a normal range of 0.5 to 0.7 in healthy adults.

If stable, then risk stratify using Oakland score:

A patient with an Oakland score ≤8, is classified as a MINOR bleed and suitable for discharge from A&E and referral for outpatient colonoscopy. 6% of patients presenting with LGIB have an underlying bowel cancer, hence, endoscopy within 2 weeks is indicated in higher risk cases.

A patient with an Oakland score >8 is classified as a MAJOR bleed, and is likely to benefit from hospital admission and colonoscopy on the next available list.

Oakland score
References include:
wiki/gastroenterology/haematemesis_and_melaena.txt · Last modified: 2023/04/25 14:16 by 127.0.0.1
CC Attribution-Share Alike 4.0 International Except where otherwise noted, content on this wiki is licensed under the following license: CC Attribution-Share Alike 4.0 International